Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients

Figure 1 The genomes of hepatitis C virus[2].

Figure 2 Distribution of hepatitis C virus patients vs Fibrotic stages. A: Gender-specific distribution of hepatitis C virus patients; B: Age distribution of hepatitis C virus infected patients.

Figure 3 miRNA Expression regulation of hepatitis C virus patient’s vs fibrotic stages. A: MiR-122; B: MiR-199-a; C: MiR-155; D: MiR-21.

Figure 4 Area under the receiver operating characteristic curve for special investigations (four miRNAs). A: Mild; B: Moderate; C: Severe; D: Overall fibrosis cases.

Figure 5 Bayesian analysis for severity of liver fibrosis. A: Non-fibrotic; B: Mild fibrosis; C: Moderate fibrosis; D: Severe fibrosis.